Abstract. Mathematical models for cancer chemotherapy as optimal control problems are considered. Results on scheduling optimal therapies when the controls represent the effectiveness of chemotherapeutic agents, or, equivalently, when the simplifying assumption is made that drugs act instantaneously, are compared with more realistic models that include pharmacokinetic (PK) equations modelling the drug's plasma concentration and various pharmacodynamic (PD) models for the effect the concentrations have on cells.
1.
Introduction. Mathematical modelling of cancer chemotherapy has more than four decades of history (e.g., [2, 5, 17, 18, 22, 23] ) and has contributed to the development of several qualitative ideas for chemotherapy scheduling. But the more difficult part of this research lies in generating quantitative practical results. The reasons for this lie in both biomedicine and mathematics. On the biological side, important cell processes still are not fully understood, since the complexity of the underlying biological processes is difficult to capture. Thus our understanding of the dynamics is incomplete, especially in multidrug treatments when synergistic or antagonistic relations may not be clear. Another problem is that crucial parameters in the modeling may not be known or may simply vary too much from case to case so that data are not readily transferable. On the mathematical side, the only feasible approach for dealing with realistic (and thus necessarily high-dimensional, complicated, and intricate) models is through numerical simulation studies relying on computational power (as for the model underlying [21] ). But if there is high uncertainty or a large range of relevant parameter values from patient to patient, then in chemotherapy simulations inherently are of limited quantitative practical value as well. As Goldie has observed, "The best average treatment may be the poorest option for a particular patient" [7] . Theoretical analysis, on the other hand, is limited to small and hence overly simplified models whose results are not applicable quantitatively. Nevertheless, their analysis can further our understanding of some simplified aspects of the overall system, a necessary step toward the goal of analyzing more medically relevant models. For example, these investigations can point out how sensitive some protocols are with respect to specific parameters and thus indicate the relevant and less relevant medical parameters in quantitative approaches.
Mathematically, cancer chemotherapy can be viewed as a control system with the state of the system, N , given by the numbers of cells of various type in specific compartments. The number of compartments determines the dimension n of the system. For example, the compartments can correspond to the phases of the cell cycle or some clusters of these, and the components of N give the average number of cancer cells in these compartments as in the models in [23, 25] . If the emphasis is on healthy cells rather than on cancer cells, the state might consist of the number of bone marrow cells as in [6] . The control, u, typically represents the drug dosage or, in simplified models, the effect the drugs have on normal and cancer cells. Since chemotherapeutic agents affect normal cells as well as cancer cells, the objective becomes to minimize the number of cancer cells over a fixed therapy interval while keeping the toxicity to the normal tissue at an acceptable level. In such a formulation, side effects typically are modeled implicitly only by minimizing the total amount of drugs given. If the side effects are more in the focus of the model, the objective may be to maximize the bone marrow cells while trying to administer as much drugs as possible. Either way, these approaches naturally can be formulated as optimal control problems.
In view of the complexity of the real medical problem, it makes sense to start with the analysis of simplified models and then add increasingly complex and medically more realistic features to the model. In this sense, a commonly made simplification is to identify the drug dosage with its concentration or even with its effects. In reality, these clearly are different phenomena and their relationships are studied under the names of pharmacokinetics (PK) and pharmacodynamics (PD). In this paper, we consider a general mathematical model for cancer chemotherapy described by a bilinear system, but add pharmacokinetic equations that model the drug's concentration in the body plasma and also allow for pharmacodynamic effects in modeling the effectiveness of the drugs. Thus, in principle, the dynamics of drug delivery and effectiveness can formally be incorporated in the models. But the models used here are still small and clearly are not comprehensive. For example, the important aspect of drug resistance is not included.
In section 2, a general mathematical model with the dynamics given by a bilinear system is formulated that is then augmented by models for PK and PD in section 3. An analysis of optimal controls using the Maximum principle is given in section 4, and the optimality of singular controls is investigated. These results are illustrated for two simple two-dimensional models in section 5. For these examples, it is shown that the optimality status of singular controls does not change under the addition of linear PK and PD models. For both models, which have been initially analyzed in [14] and [16] , singular controls are not optimal when linear PK and PD models are added. However, with nonlinearities in the PK/PD equations, singular controls become viable candidates for optimality.
2.
A general compartmental model for cancer chemotherapy as optimal control problem.
2.1.
Dynamics. Many models for cancer chemotherapy considered in the literature have an underlying dynamics described by a bilinear system of the form
where A and B i are n × n matrices, B i = 0, and n is the number of compartments.
(For example, see [6, 12, 13, 23] .) The components of the vector N denote the number of cancer (or other) cells in the compartments, and the controls u i often represent the drug dosages of various drugs and take values in compact intervals [α i , β i ] ⊂ [0, ∞) with α i = 0 in these cases. Initially all components of N 0 are positive. An obvious state space constraint for these models is that the number of cells remains positive. However, with correct modeling this constraint should not need to be imposed. 1 Mathematically, a simple sufficient condition for this to hold, which often can easily be verified, is that all the matrices A +
Proof. For any control u defined on [0, ∞), (1) is a linear system with bounded coefficients, and thus solutions exist over [0, ∞). Define τ as the supremum over all times η such that all components N i (t) are positive on [0, η]:
Since all components of N 0 are positive, τ > 0. If τ < ∞, then let ρ denote one of the components i of N for which N i (τ ) = 0. Then ρ satisfies a first-order ordinary differential equation (ODE) of the formρ = αρ + β with ρ(0) > 0 and β(t) ≥ 0 for 0 ≤ t ≤ τ. Hence,
Contradiction.
In the cell-cycle-specific compartmental models for cancer chemotherapy developed in [23] , this condition is always satisfied since there are outflows only from the ith compartment but no direct return flows into the ith compartment. Thus, if N i (0) > 0 for all i = 1, . . . , n, then N i (t) > 0 for all i = 1, . . . , n and all times t > 0. Therefore the physical state-space constraints N i (t) ≥ 0 for i = 1, . . . , n of our model will never be active and need not be stated explicitly. We therefore henceforth assume that the system Σ 0 is positive invariant in this sense.
2.2.
Objective. The aim of any treatment is to kill the cancer or at a minimum to curtail its further spread while keeping the side effects of treatment on the normal tissue acceptable. Mathematically there are many (nonequivalent) ways of modeling this. In this paper, we consider a linear (L 1 -type) objective of the form 2.3. Example 1: Phase-specific models for cancer cells. Each cell passes through a sequence of phases from cell birth to cell division. The starting point is a growth phase G 1 , after which the cell enters a phase S where DNA synthesis occurs. Then a second growth phase G 2 takes place in which the cell prepares for mitosis or phase M . Here, cell division occurs. Each of the two daughter cells may either reenter phase G 1 or simply lie dormant in a separate phase G 0 for some time until reentering G 1 , thus starting the entire process all over again. These distinctions are important, because most drugs are active in a specific phase of the cell cycle. For example, so-called spindle poisons destroy a mitotic spindle and are active in mitosis. In the modeling, G 2 and M often are combined into one compartment, since the boundaries between these phases are difficult to establish and many killing agents, such as paclitaxel (Taxol), mainly affect cells during their division and thus are G 2 /M specific. The reason for this is that the cell walls become very thin and porous in mitosis M , and so the cell is more vulnerable to an attack during this phase. Drug treatment influences the cell cycle in many other ways besides cell-killing; blocking and recruitment agents also play important roles. Blocking agents slow the transitions of the cells through the cell cycle and thus impede the tumor's growth, while recruiting agents make cancer cells leave the dormant stage G 0 , where they typically are not susceptible to any chemotherapy.
Taking into account phase specificity naturally leads to compartmental models for cancer chemotherapy. One class of probabilistic models of this type was developed in [23, 25] . Depending on the number and types of therapeutic agents considered, the phases of the cell cycle are clustered into compartments, with the state representing the average number of cells in each compartment and the control representing the dosages or effects of the various drugs. The dynamics describes the in-and outflows between the compartments in the presence of the control, that is, under therapy. The transit times of cells through phases of the cell cycle vary, particularly in malignant cells. If an exponential distribution is used to model the transit times, then for the averages, a bilinear system of the type Σ 0 arises, with the parameters of the matrices related to the inverse of the expected transit times [23] .
The simplest model arises when a single G 2 /M -specific killing agent is considered. Then it is natural to combine the dormant phase G 0 , the first growth phase G 1 and the synthesis phase S into the first compartment, while the second consists of the second growth phase G 2 and mitosis M . If N i (t), i = 1, 2, denote the number of cancer cells in the ith compartment at time t, then a single-input two-dimensional system of the formṄ
arises with
and control constraint 0 ≤ u ≤ 1. The coefficients a i represent the inverse mean transit times of the cells through the ith compartment [23] .
If additional drugs are considered, the numbers of controls and compartments increases as in examples including blocking agents [12] , recruiting agents, or both [13] . For example, the insensitivity of dormant cells to anticancer drugs is a major problem for leukemia. A mathematical model in which active recruitment of the cells in the dormant stage G 0 through cytokines [26] is modeled distinguishes the dormant phase G 0 from the first growth phase G 1 and combines the remaining phases S, G 2 , and M . This leads to a three-dimensional system of the forṁ
where
and
The control u 1 , 0 ≤ u 1 ≤ 1, represents the killing agent, and a recruiting agent u 2 is applied to reduce the average sejour time in the quiescent phase. As a result, the average transit time through the compartment G 0 is reduced, increasing the outflow by a factor 1 + u 2 , 0 ≤ u 2 ≤ w max . The control u 2 = 0 corresponds to no drug being applied, while u 2 = w max occurs with a full dose. It is assumed that newly born cells either enter G 1 and immediately start the cell division process or that they enter the dormant stage G 0 with probabilities b 0 and b 1 , b 0 + b 1 = 1.
Example 2: Models for bone-marrow cells.
A different type of model that goes back to Eisen [5] and fits the same mathematical pattern was considered by Panetta [19] . For many drugs, the limiting tissue is hemopoietic (i.e., related to blood-cell formulation). Mature cells of these renewing tissues are formed through differentiation from the self-renewing stem-cell population in the bone marrow, and it is generally accepted that "ideal cancer treatment would aim to bring about minimal normal stem cell kill" [9] . Toxicity to the bone marrow thus is one of the main limiting factors in chemotherapy and should be taken into account. This model focuses on this aspect of treatment.
The model distinguishes proliferating cells P from quiescent (or dormant) cells Q in the bone marrow. The growth rate of the proliferating cells is denoted by γ, and the transition rates from proliferating to quiescent cells and vice versa are denoted by α and β, respectively. The rate at which bone marrow enters the blood stream is denoted by ρ, and the natural death rate of the proliferating cells is called δ. It is assumed that all these parameters governing the cell cycle remain constant over the time horizon considered and that chemotherapy kills proliferating cells but that quiescent cells are not affected by the agent. The overall dynamics of the controlled system is described bẏ
with all initial conditions positive. If we set N = (P, Q), the general form of the dynamics is given by the bilinear systeṁ
with
2.5. Brief summary of existing results. In earlier research, we have analyzed both specific models from the class Σ 0 [11, 12, 13] as well as the structure of its solutions in the general case [24] . The necessary conditions for optimality for these models given by the Pontryagin maximum principle [20] single out bang-bang and singular controls [1, 10] as the prime candidates, although they do not fully restrict the candidates for optimal controls in general. Bang-bang controls correspond to protocols in which a full dose is administered separated by rest periods when no dose is given. Singular controls correspond to specific types of protocols with timevarying partial doses. However, with the aid of high-order necessary conditions for optimality, such as the generalized Legendre-Clebsch condition or the Goh condition [10] , it has been shown for each of the specific models considered that singular controls are not optimal. In fact, for all models considered falling into the type of Example 1, singular controls are locally maximizing rather than minimizing [11, 12] , and they also are not optimal for the bone-marrow model of Example 2. For all these models, easily verifiable sufficient conditions for local optimality of bang-bang trajectories [11, 24] have been developed using the method of characteristics. These results agree with medical practice of giving full-dose chemotherapy sessions with complete rest periods in between. Giving continuously varying partial doses as they would occur for singular arcs is in fact not optimal for problem (P min / max ).
Models including pharmacokinetics and pharmacodynamics (PK/PD).
In these earlier models, the drug's dosage is identified with its concentration and effects. Here we investigate whether and to what extent the qualitative results about optimal controls will change if more generally one augments model (1) with PK equations that model the drug's concentration in the body and also adds functions e = s(c) as a model for PD. These are important aspects and make the models more medically relevant and realistic.
3.1. Pharmacokinetics. In (1), as in most other models, the variable u actually represents the effects of the drugs. Mathematically equivalent, the relations between the drug dosage and the effects of the drugs are considered instantaneous. We augment the class of compartmental models for cancer chemotherapy defined by (1) with PK equations that model the time evolution of the drug's concentration. We first consider a single chemotherapeutic agent. Simple models considered in the literature use a first-order linear system to represent the dynamics for the drug concentration c in the plasma. The model itself is one of exponential growth and decay as it is commonly used as the model for continuous infusions. Here, we more generally consider a bilinear system of the forṁ
where f and h are positive constants, but g is arbitrary. This model introduces some mild nonlinearities and allows for the feature that concentrations build up to their maximum level at a different rate from that at which the drug is cleared by the system if no additional drugs are given. This makes sense because these are physiologically different procedures. For example, if c(τ ) =c and a constant control u(t) ≡ū is used for t > τ , then
For a linear system (g = 0) the concentrations therefore build up to their maximal value exponentially in the same way that they decay when no drug is given, namely, at rate f . For the bilinear model in the absence of additional drugs given, the concentration still decays exponentially at rate f , but it is possible to differentiate the speed of the build up to f +ūg. Thus g > 0 implies a faster buildup of the concentration than the eventual clearance of the drug. Figure 1 illustrates the different behaviors for a system of the formċ = −(1+ug)c+hu for g = 0, 1, 2, 3 when an initial dose u ≡ 1 is given on the interval [0, 2]. The normalization h = 1 + g has been made to set the maximal achievable concentration to c = 1 for all cases. The linear system g = 0 corresponds to the lower solid line for which the concentration grows to less than 90%, while the curves for g = 1 (dash-dot), g = 2 (dash), and g = 3 (upper solid curve) show an acceleration in the buildup of the concentration. After the drug has been stopped, the decay follows the same exponential law in all the cases, and the curves for positive g are very close to each other. We only note that the dynamic response can also be tailored to bolus injections by properly choosing the parameters simply with the understanding that the time interval of application is very small.
The bilinear model (13) represents a first attempt at introducing nonlinearities into the PK model and could be replaced with more complicated nonlinear structures. But then our analysis in section 4 below would need to be adjusted and carried out anew. In this paper, our interest is to explore the effect of nonlinearities on the structure of optimal solutions, and for this the model (13) is a good starting point. For multidrug treatments it is still a reasonable first-order approximation to assume that the concentrations of the different drugs build up independently. Thus if we add an equation of the type (13) for each of the drugs and replace the drug dosage in the dynamics by its concentration, then the combined dynamics becomeṡ
the objective remains unchanged.
3.2. Pharmacodynamics. However, (14) does not properly account for the effect e the drug concentration c has on the cancer cells. For instance, in the models of Example 1, it is assumed that the effect e of the drug is proportional to the number of ineffective cell divisions in the G 2 /M phase; that is, e = sc and s is called the effectiveness of the drug. 
which more accurately describes the effectiveness for high concentrations and sigmoidal functions [8] try to capture the behavior at both lower and higher concentrations. Examples of these are s(c) = E min + E max − E min 1 + 10 n(log EC50−c) (17) or its approximation
where n is a positive integer greater than 1. In these equations, E max and E min denote the maximum and minimum effects, respectively, and EC 50 denotes the concentration at half the maximum effect; these are commonly used parameters in pharmacology. The E max model is reasonable for fast-acting drugs, which then saturate at high concentrations while the sigmoidal models more accurately approximate the effectiveness at both lower and higher concentrations. In our analysis below we only assume that the functions s i satisfy s i (0) = 0, are strictly increasing and twice continuously differentiable with values in intervals [0,s i ], 0 <s i < ∞, possibly only reaching levels i asymptotically for full dose. For a linear function or other unbounded models, this can be guaranteed by appropriately choosing the model parameters in (13) .
In a multidrug treatment, however, these formulations are only applicable if the drugs act in different ways. Clearly, if there are two or more killing drugs that essentially act in the same phase of the cell cycle, their combined effectiveness depends on the concentrations of all of them and all their possible synergistic properties. To the best of our knowledge, these types of interactions are not well understood even for the most commonly used drugs, and therefore usually similarly acting drugs are bundled into one control in mathematical models. In the model below this is assumed, or equivalently, the controls correspond to qualitatively different drugs (e.g., killing agents versus recruiting agents) that act in different compartments in the model. Then we can formulate the overall dynamics aṡ
Since side effects of drugs are manifold and not necessarily restricted to the killing agents, we retain the drug dosage u as a measure in the integral of the objective. Thus, overall the problem now becomes:
(Q min / max ): choose a Lebesgue measurable function u : [0, T ] → U that minimizes (or maximizes) objective (3) subject to dynamics (19) and (20) . 4 . Analysis of the model with PK/PD equations.
4.1.
Necessary conditions for optimality. First-order necessary conditions for optimality are given by the Pontryagin maximum principle [20, 1] . It is easily seen that extremals are normal and therefore these conditions reduce to the following statement: If u * is an optimal control with corresponding trajectory (N * , c * ), then there exist absolutely continuous functions λ and µ, which we write as row vectors,
* , satisfying the adjoint equations with transversality condition,
such the optimal control u * minimizes (or maximizes) the Hamiltonian H,
For the sake of definiteness, we henceforth consider the minimization problem. We call a pair ((N, c), u) consisting of an admissible control u with corresponding trajectory (N, c) for which there exist multipliers (λ, µ) such that the conditions of the maximum principle are satisfied an extremal (pair), and the triple ((N, c), u, (λ, µ)) is an extremal lift (to the cotangent bundle). 
Since the components of r are positive, we have σ < T . If σ > −∞, let ρ denote one of the components i of λ for which λ i (σ) = 0. Again ρ satisfies a first-order ODE of the formρ = αρ + β with ρ(T ) > 0, but now β(t) ≤ 0 for τ ≤ t ≤ T. Hence
We henceforth assume that all states N and costates λ are positive. Sign properties of the multipliers µ i depend on the coefficients of the matrix B i . If τ is a zero of µ i , thenμ
Since s i is strictly increasing, for example, we have the following proposition.
Proposition 4.2. If all entries of the matrix B i are nonpositive (resp. nonnegative), then the multiplier µ i is negative (resp. positive) for t < T .
Proof. We only consider the case when the entries are nonpositive. Then, since B i = 0, at least one entry must be negative, and thus λ(t)B i N (t) < 0 for all t. Therefore,μ i (τ ) > 0 whenever µ i (τ ) = 0. Since µ i (T ) = 0, it follows that µ i is negative for t < T . More generally, similar results can be proven if it can be asserted that λ(τ )B i N (τ ) < 0 whenever µ i (τ ) = 0. The conditions of the maximum principle in some instances allow to do this.
4.2.
Bang-bang and singular controls. The Hamiltonian H of the optimal control problem is of the form
Since the control set is an interval,
, the minimization condition is equivalent to m scalar minimization problems for each control u i , and thus we have
The functions Φ i are called the corresponding switching functions. Note that Φ i (T ) = i ≥ 0, and thus optimal controls will always end with an interval where u i (t) ≡ α i if a positive weight is put on the corresponding drug. Intuitively this is clear, since the addition of a pharmacokinetic model generates a delay in the effectiveness of the control, and thus because since side effects still are measured instantaneously in the model in terms of the drug dosage, it is not optimal to give drugs until the very end of therapy. A priori, the controls are not determined by the minimum condition at times when Φ i (t) = 0. However, if Φ i (t) ≡ 0 on an open interval, then all derivatives of Φ i (t) also must vanish, and this may determine the control. Controls of this kind are called singular, while we refer to the constant controls as bang controls. Optimal controls then need to be synthesized from these candidates through an analysis of the switching function. For example, if Φ(τ ) = 0 butΦ(τ ) = 0, then the control has a switch at time τ and must be bang-bang near τ . To analyze the structure of the optimal controls, we therefore need to analyze the switching function and its derivatives. A simple direct computation shows that these derivatives are given bẏ
This allows forΦ i (τ ) to vanish at points where Φ i (τ ) = 0. For example, if the entries of B i are nonpositive, then
Since s i > 0, we always have a difference of negative terms, which allows for the possibility of singular arcs. If the control u i is singular on some open interval I (i.e., if the switching function Φ i vanishes on I), minimization of the Hamiltonian (23) is inconclusive and does not determine the value of the control. However, in this case all derivatives of the switching function also vanish identically on I. Typically the singular controls can be computed by differentiating the switching function in time until the control variable explicitly appears in the derivative, say in Φ Otherwise the singular arc is not admissible. For a single-input system that is linear in the control, it is well known [10] that d must be even, say d = 2k, and k is called the order of the singular arc. In principle, this order can vary with time over the interval I. If it is constant on the interval I, then it is a necessary condition for minimality of a singular arc of order k, the so-called generalized Legendre-Clebsch condition [10, 1] , that
along the extremal. Note that the term ∂H ∂u = Φ in (30) represents the switching function for the problem. The situation becomes more complicated in the multiinput case, but in our model the controls are sufficiently decoupled so that the single-input results suffice.
Differentiating (29) once more and looking for singular arcs of order 1, we compute
For later use, we state the following formula that follows by a direct computation.
Lemma 4.1. For any n × n matrix R, the derivative of Ψ(t) = λ(t)RN (t) along solutions N of (19) and λ of (21) is given bẏ
where [A, B] = BA − AB denotes the commutator (or Lie-bracket) of A and B.
does not depend on the control. It therefore follows from the dynamics and adjoint equations that
ButΦ ≡ 0 along the singular arc, and therefore using (29) we get
and for the minimization problem, it is a necessary condition of optimality of the singular arc that this quantity is nonpositive. Further analysis of this condition depends on the signs of λB i N and the multiplier µ i and needs to be done on a case-by-case basis. Here, as an example, we consider the scenario when all entries of B i are nonpositive. This applies to both the two-compartment cancer model defined by (5) and the model for bone-marrow depletion in (12) . In this case, by Propositions 4.1 and 4.2, it follows that both λB i N and µ i are negative. Usinġ Φ ≡ 0, this implies that h i − g i c i is positive along a singular arc. Summarizing, we have the following proposition. 
For the case of a linear PK equation (g i = 0), singular controls are not optimal in regions where s i is strictly convex.
In particular, under Assumption (A) with a linear PK model and a sigmoidal PD equation for drug i, singular controls u i are not optimal for low concentrations, but the Legendre-Clebsch condition is satisfied, and thus feasible singular arcs in fact can be expected to be locally optimal at high concentrations. Singular controls do always satisfy the Legendre-Clebsch condition for the E max model in this case. (35) is satisfied trivially, and the singular arc is of higher order. While having simple PK and PD, this case nevertheless becomes more involved now since interactions between the drugs and their concentrations come into play. We briefly give the relevant computations. Again, it is assumed that Φ i and thus also all its derivatives vanish on some open interval I:
Since the second derivative does not explicitly depend on the control u i , the singular arc is of higher order. What makes the computation still manageable is that this derivative also does not depend on the particular concentration c i of the drug dose u i , which is singular. Differentiating once more gives
In the fourth derivative formally, derivatives of the other controls u j , j = i, also are needed, and we assume they exist (e.g., bang-bang or itself differentiable singular controls). Differentiating once more, however, any term arising from the second and third term in (39) does not depend on u i , and overall we get the following necessary condition for optimality of the singular arc:
For a single-input system this simplifies to ∂ ∂u
5. Simulations and comparisons. We include some brief simulations for the two-compartment model in Example 1 and the bone-marrow model in Example 2 to show that the addition of linear PK and PD models does not change the qualitative structure of solutions: solutions are bang-bang with one switching, and linear PK and PD models only shift the location of the switching. 
violating (41). Thus, in this case, singular controls are not optimal, and optimal controls still are bang-bang, as in the model without PK equations [11] . Using a version of the gradient method for the calculation of extremal bang-bang controls developed by Duda [4] , we computed the locally optimal controls shown below. (The local optimality of each run can be established using the algorithm developed in [11] , but this will not be discussed here.) The length of the therapy interval is T = 10, and as parameter values we used a 1 = 0.197 and a 2 = 0.356. In the objective, we set r 1 = r 2 = 1, q 1 = q 2 = 1 and picked = 1; in the linear PD equation, we set s = 1. The initial condition was chosen as the steady-state value of the uncontrolled system. For these parameter values with the total number of cells normalized to 1, about 70% of the cancer cells are in the first compartment and about 30% are in the second compartment [14] . Figure 3a shows the control and corresponding switching function for the model without PK while Figure 3b show these data for runs with a linear PK equation of the formċ = −c + u. By choosing h = f in this equation, we normalize the maximum concentration to 1 in agreement with the choice s = 1 for the model without PK and PD; otherwise results are not comparable. In all the figures, the optimal controls are given by the solid line, and the corresponding switching functions are given by a dashed line. Optimal controls are bang-bang, with one switching from u = 1 to u = 0. As linear PK and PD equations are added, the qualitative behavior of the solutions remains the same, but the switching occurs slightly earlier, which is caused by the delay type effect of PK. The slower the PK dynamics is, the more pronounced this effect becomes.
5.2.
A two-compartment model for bone-marrow cells. As in the example above, Assumption (A) of Proposition 4.3 holds, and singular controls are of order 2. But since Example 2 is a maximization problem, the signs in the LegendreClebsch condition are reversed, and now it is a necessary condition for optimality of a singular arc that
Using (12), we have B 2 = −B, and since alsoΦ ≡ 0 along a singular arc, we get
Hence (all quantities are evaluated along the singular lift)
Direct calculations show that
also violating the Legendre-Clebsch condition. Hence, all singular arcs locally minimize the objective.
Again using the version of the gradient method for the calculation of extremal bang-bang controls developed by Duda [4] , we computed the locally optimal controls shown below. (The local optimality of each run can be established using the algorithm developed in [15] and is not discussed here.) The length of the therapy interval is T = 10, and we used the following parameter values taken from [6] : α = 5.643, β = 0.48, γ = 1.47, δ = 0, and ρ = 0.164. In the simulations, we set s = 1, r 1 = r 2 = 1, and q 1 = q 2 = 1 and picked = 0.5. As above, the initial condition was chosen as the steady-state value of the uncontrolled system when about 10% of the bone-marrow cells are in their proliferating state [16] . Figures 4a  and 4b show optimal controls and corresponding switching functions for the models without PK and a linear PK equation of the formċ = −c + u, respectively. As above, choosing h = f in this equation normalizes the maximum concentration to 1 in agreement with the choice s = 1. In each case, the control is bang-bang with one switching from u = 0 to u = 1. Since the objective now is maximized and the effect is described in terms of the bone marrow, the negative effects of the drug are delayed by the PK equation, and thus the optimal control now -contrary to the cancer model above -ends with a full dose. This delay effect also accounts for the fact that the controls switch earlier, since the negative effects lag behind. The faster the concentrations build up, however, the smaller this effect is, and for f = 5 (not shown), it is almost negligible.
6. Conclusion. In this paper, we initiated the analysis of optimal controls for a class of models of cancer chemotherapy when pharmacokinetics and pharmacodynamics of the drugs are included. Our results show that the geometric properties of these models have a direct influence on the type of controls that are optimal. For the examples considered here, singular arcs remain not optimal if linear PK models and PD functions s are used and only small quantitative changes in the switching times of bang-bang controls are generated, but no qualitative changes occur. For more general PK models and PD functions s, this does not necessarily hold. Although singular controls are still not optimal for regions where s is strictly convex (typically this holds for low concentrations), the optimality status changes as s becomes concave (as is typically the case for high concentrations). This suggests a structure of optimal controls, which provide a quick initial boost in terms of bang-bang controls and then regulate the concentration through slowly varying infusions. Similarly, in the case of a bilinear (or more generally nonlinear) PK equation, the structure changes and singular controls representing protocols with partial doses can be optimal. For the bilinear model, the sign of the parameter g matters, and depending on whether the problem is formulated as minimization or maximization for g > 0, respectively, g < 0 singular controls satisfy the necessary conditions for optimality. Intuitively, in this case, once the drug's concentration is built up, the injection of smaller time-varying doses can be used to maintain a high effectiveness of the drug, which by itself slowly decays. Although the model is characterized through a number of cell-cycle-specific parameters, our analysis for these examples does not depend on the actual values of these parameters, but it is the type of PK and PD model that determines the class of optimal controls. Research in the direction of analyzing the structure of optimal controls, especially when singular arcs become candidates, is still ongoing.
In conclusion, although linear PK and PD models do not change the qualitative structure of optimal controls and, at least in the models considered here, lead only to small quantitative changes, allowing for more complex nonlinear forms for PK and PD in the model introduces singular controls as viable candidates for optimality. Their analysis, especially a synthesis with bang-bang controls, is a mathematically much more difficult problem and still needs to be addressed in further research.
